Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $25.60

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have earned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $25.60.

ATXS has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, December 10th. Oppenheimer raised their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its position in Astria Therapeutics by 152.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after purchasing an additional 189,727 shares during the period. FMR LLC raised its holdings in shares of Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Astria Therapeutics during the 3rd quarter worth about $613,000. Vestal Point Capital LP boosted its holdings in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares during the period. Finally, Sofinnova Investments Inc. acquired a new position in shares of Astria Therapeutics in the second quarter valued at approximately $552,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

Shares of ATXS opened at $9.56 on Thursday. The business’s 50-day moving average is $10.65 and its two-hundred day moving average is $10.69. The company has a market capitalization of $539.51 million, a P/E ratio of -4.57 and a beta of 0.67. Astria Therapeutics has a fifty-two week low of $5.94 and a fifty-two week high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.